Search clinical trials for: Booster response

Total 13707 results

University Hospital, Grenoble
National Agency for Research on AIDS and Viral Hepatitis (ANRS)

Not yet recruiting

Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination (VITAMIN)

Liver Transplantation | Kidney Transplantation | HBV

France
IRCCS Sacro Cuore Don Calabria di Negrar

Recruiting

Understanding Adaptive Immune Response After COVID-19 Vaccination Boosters to Improve Vaccination Strategies in Vulnerable Groups. (COVaxFragile)

COVID-19

Italy
Assistance Publique - Hôpitaux de Paris

Recruiting

Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine. (LymphoBOOST)

COVID-19

France
University of Zurich
Merck Sharp & Dohme LLC

Recruiting

Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination (MIPS)

Measles | Rubella | Mumps

Switzerland
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Vaccine Responses in Patients With B Cell Malignancies

Lymphoma

United States
Shanxi Medical University

Not yet recruiting

The Immunogenicity and Persistence of Booster Dose With Hepatitis B Vaccine in College Students

Hepatitis B Vaccine
Jeffrey Curtis
Bristol-Myers Squibb; Eli Lilly and Company; University of Pennsylvania; Novartis; Pfiz... and other collaborators

Recruiting

COVID-19 VaccinE Response in Rheumatology Patients (COVER)

Rheumatoid Arthritis | Spondylarthritis | Psoriatic Arthritis

United States
Mahidol University
Ministry of Health, Thailand; Bhumirajanagarindra Kidney Institute, Thailand

Recruiting

Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients (Enhance)

ESRD | Influenza Vaccine | Seroprotection

Thailand
National Taiwan University Hospital
Ministry of Science and Technology, Taiwan; Academia Sinica, Taiwan

Recruiting

The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort (IRHBRVD)

Hepatitis B | Vaccination; Infection | Preventable Disease, Vaccine

Taiwan
dafna yahav

Not yet recruiting

Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response (WHO)

Immunosuppression | COVID-19 Acute Respiratory Distress Syndrome
Children's Hospital of Chongqing Medical University

Recruiting

Efficacy of Hepatitis B Vaccine Boosters Among Neonatally Vaccinated Children in Chongqing

Hepatitis B Vaccine Adverse Reaction

China
Queen Saovabha Memorial Institute

Recruiting

Immune Responses and Immunological Tolerance After Rabies Booster Vaccination in HIV-infected Adults

Rabies

Thailand
Queen Saovabha Memorial Institute
Chulalongkorn University

Recruiting

Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults

Rabies

Thailand
Albert Einstein College of Medicine
Pancreatic Cancer Action Network

Terminated

Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer

Pancreatic Cancer

United States
National Institute of Allergy and Infectious Diseases...
Rho Federal Systems Division, Inc.; Autoimmunity Centers of Excellence

Completed

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Systemic Lupus Erythematosus (SLE) | Multiple Sclerosis (MS) | Rheumatoid Arthritis (RA) | Juvenile Dermatomyositis (JDM) | Juvenile Idiopathic Arthritis (JIA) | Pemphigus Vulgaris | Systemic Sclerosis (SSc) | Pediatric SLE | Pediatric-Onset Multiple Sclerosis (POMS)

United States
GlaxoSmithKline

Completed

The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine

Virus Diseases

Czechia
Matti Sällberg

Completed

A Randomized, Phase I Study of DNA Vaccine OC-007 as a Booster Dose of COVID-19 Vaccine (OpenCorona1)

COVID-19 Respiratory Infection | COVID-19 Vaccine Adverse Reaction

Sweden
Hoffmann-La Roche

Completed

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Canada, United States
GlaxoSmithKline
CureVac

Active, not recruiting

A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults

SARS-CoV-2

Australia, United States
Oregon Health and Science University

Active, not recruiting

The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)

Rheumatic Diseases

United States
Novavax
Department of Health and Human Services

Completed

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

Covid19 | SARS-CoV Infection

United States, Mexico, Puerto Rico
Oliver Cornely, MD
European Commission; VACCELERATE

Completed

Assessing Immune Response of Different COVID-19 Vaccines in Older Adults (EU-COVAT-1)

COVID-19 | Vaccination; Infection | Vaccination Reaction

Spain, Ireland, Germany, Norway, Lithuania
Sanofi Pasteur, a Sanofi Company

Completed

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

Meningococcal Immunisation (Healthy Volunteers)

United States, Puerto Rico
SK Bioscience Co., Ltd.
International Vaccine Institute

Withdrawn

A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.

COVID-19
Sanofi Pasteur, a Sanofi Company

Completed

Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa

Pertussis Immunisation | Diphtheria Immunisation | Tetanus Immunisation | Poliomyelitis Vaccine

South Africa
Assistance Publique - Hôpitaux de Paris
IREIVAC/COVIREIVAC Network

Active, not recruiting

Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults (COVIBOOSTAnci1)

COVID-19 Vaccines

France
Region Skane

Completed

Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease (IPS-BOOSTER)

Rheumatoid Arthritis | Systemic Vasculitis | Spondyloarthritis | Systemic Lupus | Sjögren Syndrome
David Grant U.S. Air Force Medical Center

Withdrawn

Profiling Spike Protein Antibody Response Post COVID-19 Booster

Spike Protein IgG Antibody | COVID-19 Booster
National Taiwan University Hospital

Completed

Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients

Hepatitis A | Human Immunodeficiency Virus | Vaccine Response Impaired

Taiwan
Medical University of Graz

Terminated

Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster Vaccines (CoVVacBoost)

Anti-SARS-CoV-2 Antibody Response

Austria
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

Herpes Zoster

United States
Chang Gung Memorial Hospital
Medigen Vaccine Biologics Corp.

Active, not recruiting

The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine

COVID-19 | Breakthrough Infection

Taiwan
Fundação de Medicina Tropical Dr. Heitor Vieira...
Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM); XP Investimentos and other collaborators

Active, not recruiting

Immune Response of an Interchangeable Booster Vaccine Against COVID-19 Among Individuals With Risk Factors for Severity (COVACManaus2)

Healthy | Comorbidities and Coexisting Conditions

Brazil
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

Breast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | HER-2 Gene Amplification | Breast Cancer Female | HER2 Positive Breast Carcinoma | HER-2 Protein Overexpression

United States
Lahore General Hospital

Active, not recruiting

Booster Effect of mRNA Vaccine on Antibody Response for SARS-CoV-2 After Complete Vaccination With Sinos

Vaccine Reaction

Pakistan
Stony Brook University
University of North Carolina, Chapel Hill

Completed

Flu Vaccine Response in Patients on Biologic Therapies

Inflammatory Bowel Diseases | Immune Complex Diseases | Rheumatologic Disorder

United States
National Institute of Allergy and Infectious Diseases...
United States Department of Defense

Completed

Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults

HIV Infections

Uganda, Kenya, Tanzania
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

HIV Infections

Uganda, United States, Kenya, Tanzania
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults

HIV Infections

United States, Brazil
University of British Columbia
Michael Smith Foundation for Health Research

Completed

SMART ERP for the Behavioral Treatment of Youth With Obsessive Compulsive Disorder (OCD)

Obsessive-Compulsive Disorder

Canada
PATH
International Centre for Diarrhoeal Disease Research, Bangladesh

Completed

Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose

Encephalitis, Japanese
GlaxoSmithKline

Completed

A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)

Meningococcal Disease | Infections, Meningococcal

Colombia, Panama, Chile
Pfizer

Completed

Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose

Meningococcal Infection

United States, Finland, Czechia, Sweden, Denmark, Germany
University College, London
GlaxoSmithKline; Medical Research Council; University of Oxford

Completed

Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination (HIV-CORE003)

HIV

United Kingdom
GlaxoSmithKline

Completed

Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis | Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin

Thailand
Pfizer

Completed

Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination

Infections, Meningococcal

Philippines
GlaxoSmithKline

Completed

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

Infections, Meningococcal

Finland, Poland
Pfizer

Completed

The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

Infections, Meningococcal

Finland
Medical University of Vienna
Valneva Austria GmbH

Unknown

Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.

Japanese Encephalitis Vaccine

Austria
Public Health England
Institute of Child Health; National Institute of Biological Standards and Control

Completed

Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life (Sched2)

Pneumococcal Infections | Meningococcal Infections

United Kingdom

3

Subscribe